Medical devices, healthcare technology and the business of care
PMA approval · P060040

THORATEC HEARTMATE II LEFT VENTRICULAR ASSIST SYSTEM

ABBOTT MEDICAL · Decision date Apr 21, 2008

MEDTECHLEDGER EXPLANATIONP060040

What did the FDA approve?

FDA approved the Thoratec HeartMate II Left Ventricular Assist System on April 21, 2008, under PMA number P060040. The approval statement describes the device as indicated for use as a bridge to transplantation in cardiac transplant candidates at risk of imminent death from non-reversible left ventricular failure.

The statement also specifies that the HeartMate II LVAS is intended for use both inside and outside the hospital, or for transportation of ventricular assist device patients via ground ambulance, fixed-wing aircraft, or helicopter. The record does not include supplement type or supplement reason fields, so no information is present about whether this decision modified an earlier submission or addressed manufacturing changes.

FDA approval order statement

APPROVAL FOR THE THORATEC HEARTMATE II LVAS. THIS DEVICE IS INDICATED FOR USE AS A BRIDGE TO TRANSPLANTATION IN CARDIAC TRANSPLANT CANDIDATES AT RISK OF IMMINENT DEATH FROM NON-REVERSIBLE LEFT VENTRICULAR FAILURE. THE HEARTMATE II LVAS IS INTENDED FOR USE BOTH INSIDE AND OUTSIDE THE HOSPITAL, OR FOR TRANSPORTATION OF VENTRICULAR ASSIST DEVICE PATIENTS VIA GROUND AMBULANCE, FIXED-WING AIRCRAFT, OR HELICOPTER.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Apr 21, 2008

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P060040
Regulatory pathway
Premarket approval application
Product code
DSQ
Decision code
APPR
Decision date
Apr 21, 2008
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Ventricular (assist) bypass.

Product code
DSQ
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P060040 received

    Application receipt date recorded by FDA.

  2. P060040 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P060040. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P060040

Product / regulatory recordCompanyPathwayDecision dateSource
HeartMate II LVASP060040/S128
ABBOTT MEDICALPMA supplementOct 1, 2026FDA

Explore the linked device profile

Other records with product code DSQ

Product / regulatory recordCompanyPathwayDecision dateSource
Berlin Heart, Inc.PMA supplementOct 30, 2026FDA
AbbottPMA supplementOct 30, 2026FDA
Berlin Heart, Inc.PMA supplementOct 28, 2026FDA
Berlin Heart, Inc.PMA supplementOct 23, 2026FDA
ABBOTT MEDICALPMA supplementOct 19, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
6035 Stoneridge Dr., Pleasanton, CA, 94588

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records